Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

Weightloss in Menopause

Susan Brian

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

Tirzepatide Updates

Diana Isaacs

Northwestern Medicine: The Connection Between Diabetes and Heart Dis…

Northwestern Medicine Bluhm Cardiovascular Institute

S. Shah, R. Kushner

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Tirzepatide for Type 2 Diabetes

Diana Isaacs

Incretin-based Therapies in the Management of Obesity and its Comorb…

Michigan Medicine

A. Rothberg

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

Houston Methodist

T. R. Mccarty

AHA 2024 Insights: Association Between Glucagon-Like Peptide-1 Recep…

AHA 2024 Insights

V. Jaiwal

New Research: Side Effect of GLP1

Susan Brian

GLP-1 Hysteria

Scripps Health

S. Harris

Semaglutide: Where Are We Now and Where Are We Going?

McMaster University Department of Medicine

S. Boushahri, D. Lazzam, K. MacEachern

Obesity Related Asthma in Children and Adolescents

William Anderson